Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ANCN

Anchiano Therapeutics (ANCN) Stock Price, News & Analysis

Anchiano Therapeutics logo

About Anchiano Therapeutics Stock (NASDAQ:ANCN)

Advanced Chart

Key Stats

Today's Range
$3.10
$3.43
50-Day Range
$2.82
$59.00
52-Week Range
$0.51
$10.55
Volume
294,357 shs
Average Volume
3.15 million shs
Market Capitalization
$23.30 million
P/E Ratio
20.93
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive ANCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anchiano Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ANCN Stock News Headlines

ITeos Therapeutics Inc Ordinary Shares
BREAKING: The House just passed 3 pro-crypto bills!
THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. tc pixel
ENDV Endonovo Therapeutics, Inc.
See More Headlines

ANCN Stock Analysis - Frequently Asked Questions

Anchiano Therapeutics Ltd. (NASDAQ:ANCN) issued its earnings results on Monday, August, 5th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.12.

Anchiano Therapeutics (ANCN) raised $35 million in an IPO on Tuesday, February 12th 2019. The company issued 2,400,000 shares at $14.55 per share. Oppenheimer served as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Anchiano Therapeutics investors own include BioCryst Pharmaceuticals (BCRX), Bionano Genomics (BNGO), Cheniere Energy (LNG), Ocugen (OCGN), Agenus (AGEN), Allena Pharmaceuticals (ALNA) and Aileron Therapeutics (ALRN).

Company Calendar

Last Earnings
8/05/2019
Today
8/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ANCN
CIK
N/A
Fax
N/A
Employees
16
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($3.46)
Trailing P/E Ratio
20.93
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$27.12 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
36.08%
Return on Assets
27.40%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.25
Quick Ratio
3.25

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.01 per share
Price / Book
1.56

Miscellaneous

Outstanding Shares
7,420,000
Free Float
N/A
Market Cap
$23.30 million
Optionable
Not Optionable
Beta
0.93
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:ANCN) was last updated on 8/31/2025 by MarketBeat.com Staff
From Our Partners